Myeloma Minute: Treatments for Relapsed Patients

myeloma cells


| INNOVATION | Latest Research


Considerations for Relapsed Myeloma Should Match Patient, Disease, and Therapy

The increasing number of myeloma treatment choices available to patients and clinicians today can make selecting the best approach at relapsed disease a challenge. In this article, IMF Chief Medical Officer Dr. Joseph Mikhael says the simplest way to approach treatment selection is to consider the 3 major classes of drugs available for these patients: proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies.


| EDUCATION | Teleconference


Myeloma Updates 2018: Best of ASCO/EHA/IMWG

Save the Date: On Thursday, August, 2, 2018, at 4 p.m. PST / 7 p.m. EST, Dr. Brian G.M. Durie will explain what’s new and exciting from these recent major medical meetings:

  • American Society of Clinical Oncology (ASC0) 2018
  • European Hematology Association (EHA) annual meeting
  • International Myeloma Working Group (IMWG) Summit
Register now for this FREE IMF teleconference 60-minute teleconference followed by a Q&A session.




| INNOVATION | Research Grants


Sixth Annual Miracles for Myeloma 5K Race/Walk
Calling All Researchers: Submit Your Grant Applications!

The Sixth Annual Miracles for Myeloma 5K Race/Walk takes place on Saturday, September 22, 2018, beginning at 9:30 a.m. EST on a USATF-certified course in Oak Ridge Park, New Jersey. Check-in is from 8:00 to 9:15 a.m. that day, and registration ends on September 18 at midnight. Donations can be made until December, whether or not you are able to participate. Last year’s Miracles for Myeloma raised nearly $80,000 for myeloma research, funding a Senior Brian D. Novis Research Grant. Once again, we encourage you to help raise myeloma awareness and funds as we work toward a cure.

The Brian D. Novis Research Grants honor the IMF’s founder Brian Novis, who succumbed to multiple myeloma in July of 1992. The grants are awarded to researchers working in the field of multiple myeloma and related disorders, including smoldering multiple myeloma (SMM), monoclonal gammopathy of undetermined significance (MGUS), and immunoglobulin-derived amyloidosis. The 2019 grants will support senior research projects with $80,000 each and junior research projects with $50,000 each. The deadline for submitting applications is Wednesday, August 1, 2018.

Register Now Button.png


| EDUCATION | Participate


10 Reasons to Attend an IMF Educational Outreach Event

At the IMF, our goal is to help others better understand multiple myeloma. That’s why we host educational outreach events. The IMF’s Patient & Family Seminars (P&FSs) and Regional Community Workshops (RCWs) provide patients, families, and caregivers with the most up-to-date myeloma information. We hope that once you attend a P&FS or RCW, you leave with a healthy dose of positivity and a greater sense of community. If you have yet to take part in one of these events, we encourage you to read this list of the 10 Reasons to Attend an IMF Educational Outreach Event.


| ACTION | Legislation


Firefighter Cancer Registry Act Signed into Law

President Trump signed H.R. 931, the Firefighter Cancer Registry Act of 2017 into law on July 9, 2018. This new law will help researchers better understand cancer in firefighters. It creates a voluntary national registry to collect information about cancer incidence in firefighters.

Firefighters put their lives on the line by charging into burning buildings and rescuing people from dangerous situations. Sadly, the elements firefighters are exposed to while performing their heroic work may cause cancers like multiple myeloma.

The International Myeloma Foundation’s Senior Director of Public Policy and Advocacy, Robin Levy, said, “The IMF is optimistic the Firefighter Cancer Registry Act will provide our research community with the additional tools they need to better understand the increased cancer instances in firefighters. We thank Representatives Collins and Pascrell for their leadership on this important piece of legislation, and we believe this bill has potential to provide us with new knowledge that will help us keep firefighters safe on the job.”

H.R. 931 was introduced by Rep. Collins (R-NY) and Rep. Bill Pascrell (D-NJ). The House previously passed H.R 931 on September 12, 2017. However, the bill was amended in the Senate and was readdressed by the House on June 22. View the full bill below.


| #ASKDRDURIE | Dr. Durie's Weekly Web Video Series



BOSTON Trial Fact Sheet

New isatuximab Clinical Trial: the IMROZ Study

New isatuximab Clinical Trial: the IKEMA Study

New ixazomib Clinical Trials: Learn How to Participate

Join the conversation about myeloma on the Smart Patients Message Board

July 21, 2018
IMF Regional Community Workshop
Edina, MN

August 1, 2018
Laughs for Life
Hattiesburg, MS

August 24-25, 2018
IMF Patient & Family Seminar
Los Angeles, CA

September 22, 2018
6th Annual Miracles for Myeloma 5K Race/Walk
Oak Ridge Park Clark, NJ

September 22, 2018
A Mission for Matt
Mineola, NY

September 22, 2018
IMF Regional Community Workshop
Overland Park, KS

subscribe_button.png          donate_button_bottom.png
We Thank Our Sponsors:
Amgen, Celgene Corporation, Genentech, Janssen Oncology, and Takeda Oncology
and individuals like you who supported the IMF this year

Source URL: